Took some time out to read this rich discussion of CCL5 and colorectal cancer recently published as CRC is a company discussed target for Leronlimab. You can’t read this and fail to appreciate we have a game changing molecule. Don’t neglect table 2 if you peruse this article as it is a preview of coming attractions…a quiver of arrows, multiple targets for this drug, which is on sale now but people will pay any price for in the future.

https://www.tandfonline.com/doi/full/10.1080/...23.2205168